Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis

Ibrahim Batal, Mhd Bassel Ericsoussi, Joanne E. Cluette-Brown, Brian P. O'Sullivan, Steven D. Freedman, Juanito E. Savaille, Michael Laposata

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: An altered distribution of fatty acids in cells and tissues is found in patients with cystic fibrosis (CF). In this study, we assessed the potential role of plasma fatty acid analysis in the diagnosis of CF. Methods: In this 2-part study, we first used gas chromatography-mass spectrometry to analyze fatty acids in plasma from 13 CF patients and 11 controls without CF. We then used the fatty acid distribution data to identify the fatty acids or multiple fatty acid calculations most effective in identifying CF patients. Part 2 of the study was a blinded analysis of 10 CF patients and 9 controls to directly test the effectiveness of the diagnostic parameters for CF identified from the plasma fatty acid analysis. Results: In the nonblinded trial, the multiplication product of (18:2 n-6) × (22:6 n-3) (each as percentage of total plasma fatty acid) was the most effective indicator for distinguishing patients with CF from controls (P = 0.0003). In part 2 (the blinded trial), this multiplication product was also the most effective indicator for distinguishing CF patients from controls (P = 0.0008). Conclusions: The product of (18:2 n-6) × (22:6 n-3) is effective for distinguishing CF patients from persons without CF. This diagnostic marker may have value as an alternative to the sweat chloride test in selected patients being evaluated for CF.

Original languageEnglish (US)
Pages (from-to)78-84
Number of pages7
JournalClinical Chemistry
Volume53
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Cystic Fibrosis
Fatty Acids
Plasmas
Gas chromatography
Mass spectrometry
Chlorides
Sweat
Tissue
Routine Diagnostic Tests
Gas Chromatography-Mass Spectrometry

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Batal, I., Ericsoussi, M. B., Cluette-Brown, J. E., O'Sullivan, B. P., Freedman, S. D., Savaille, J. E., & Laposata, M. (2007). Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis. Clinical Chemistry, 53(1), 78-84. https://doi.org/10.1373/clinchem.2006.077008

Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis. / Batal, Ibrahim; Ericsoussi, Mhd Bassel; Cluette-Brown, Joanne E.; O'Sullivan, Brian P.; Freedman, Steven D.; Savaille, Juanito E.; Laposata, Michael.

In: Clinical Chemistry, Vol. 53, No. 1, 01.2007, p. 78-84.

Research output: Contribution to journalArticle

Batal, I, Ericsoussi, MB, Cluette-Brown, JE, O'Sullivan, BP, Freedman, SD, Savaille, JE & Laposata, M 2007, 'Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis', Clinical Chemistry, vol. 53, no. 1, pp. 78-84. https://doi.org/10.1373/clinchem.2006.077008
Batal I, Ericsoussi MB, Cluette-Brown JE, O'Sullivan BP, Freedman SD, Savaille JE et al. Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis. Clinical Chemistry. 2007 Jan;53(1):78-84. https://doi.org/10.1373/clinchem.2006.077008
Batal, Ibrahim ; Ericsoussi, Mhd Bassel ; Cluette-Brown, Joanne E. ; O'Sullivan, Brian P. ; Freedman, Steven D. ; Savaille, Juanito E. ; Laposata, Michael. / Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis. In: Clinical Chemistry. 2007 ; Vol. 53, No. 1. pp. 78-84.
@article{f59d277ba13f4e44b0c8c2460e6f4edc,
title = "Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis",
abstract = "Background: An altered distribution of fatty acids in cells and tissues is found in patients with cystic fibrosis (CF). In this study, we assessed the potential role of plasma fatty acid analysis in the diagnosis of CF. Methods: In this 2-part study, we first used gas chromatography-mass spectrometry to analyze fatty acids in plasma from 13 CF patients and 11 controls without CF. We then used the fatty acid distribution data to identify the fatty acids or multiple fatty acid calculations most effective in identifying CF patients. Part 2 of the study was a blinded analysis of 10 CF patients and 9 controls to directly test the effectiveness of the diagnostic parameters for CF identified from the plasma fatty acid analysis. Results: In the nonblinded trial, the multiplication product of (18:2 n-6) × (22:6 n-3) (each as percentage of total plasma fatty acid) was the most effective indicator for distinguishing patients with CF from controls (P = 0.0003). In part 2 (the blinded trial), this multiplication product was also the most effective indicator for distinguishing CF patients from controls (P = 0.0008). Conclusions: The product of (18:2 n-6) × (22:6 n-3) is effective for distinguishing CF patients from persons without CF. This diagnostic marker may have value as an alternative to the sweat chloride test in selected patients being evaluated for CF.",
author = "Ibrahim Batal and Ericsoussi, {Mhd Bassel} and Cluette-Brown, {Joanne E.} and O'Sullivan, {Brian P.} and Freedman, {Steven D.} and Savaille, {Juanito E.} and Michael Laposata",
year = "2007",
month = "1",
doi = "10.1373/clinchem.2006.077008",
language = "English (US)",
volume = "53",
pages = "78--84",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "1",

}

TY - JOUR

T1 - Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis

AU - Batal, Ibrahim

AU - Ericsoussi, Mhd Bassel

AU - Cluette-Brown, Joanne E.

AU - O'Sullivan, Brian P.

AU - Freedman, Steven D.

AU - Savaille, Juanito E.

AU - Laposata, Michael

PY - 2007/1

Y1 - 2007/1

N2 - Background: An altered distribution of fatty acids in cells and tissues is found in patients with cystic fibrosis (CF). In this study, we assessed the potential role of plasma fatty acid analysis in the diagnosis of CF. Methods: In this 2-part study, we first used gas chromatography-mass spectrometry to analyze fatty acids in plasma from 13 CF patients and 11 controls without CF. We then used the fatty acid distribution data to identify the fatty acids or multiple fatty acid calculations most effective in identifying CF patients. Part 2 of the study was a blinded analysis of 10 CF patients and 9 controls to directly test the effectiveness of the diagnostic parameters for CF identified from the plasma fatty acid analysis. Results: In the nonblinded trial, the multiplication product of (18:2 n-6) × (22:6 n-3) (each as percentage of total plasma fatty acid) was the most effective indicator for distinguishing patients with CF from controls (P = 0.0003). In part 2 (the blinded trial), this multiplication product was also the most effective indicator for distinguishing CF patients from controls (P = 0.0008). Conclusions: The product of (18:2 n-6) × (22:6 n-3) is effective for distinguishing CF patients from persons without CF. This diagnostic marker may have value as an alternative to the sweat chloride test in selected patients being evaluated for CF.

AB - Background: An altered distribution of fatty acids in cells and tissues is found in patients with cystic fibrosis (CF). In this study, we assessed the potential role of plasma fatty acid analysis in the diagnosis of CF. Methods: In this 2-part study, we first used gas chromatography-mass spectrometry to analyze fatty acids in plasma from 13 CF patients and 11 controls without CF. We then used the fatty acid distribution data to identify the fatty acids or multiple fatty acid calculations most effective in identifying CF patients. Part 2 of the study was a blinded analysis of 10 CF patients and 9 controls to directly test the effectiveness of the diagnostic parameters for CF identified from the plasma fatty acid analysis. Results: In the nonblinded trial, the multiplication product of (18:2 n-6) × (22:6 n-3) (each as percentage of total plasma fatty acid) was the most effective indicator for distinguishing patients with CF from controls (P = 0.0003). In part 2 (the blinded trial), this multiplication product was also the most effective indicator for distinguishing CF patients from controls (P = 0.0008). Conclusions: The product of (18:2 n-6) × (22:6 n-3) is effective for distinguishing CF patients from persons without CF. This diagnostic marker may have value as an alternative to the sweat chloride test in selected patients being evaluated for CF.

UR - http://www.scopus.com/inward/record.url?scp=33846009841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846009841&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2006.077008

DO - 10.1373/clinchem.2006.077008

M3 - Article

VL - 53

SP - 78

EP - 84

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 1

ER -